期刊文献+

特异性阻断Kv1.5通道对心房颤动患者缝隙连接蛋白40表达的影响 被引量:6

Effect of the protein expressions of gap junction Cx40 by using Ibutilide to selective act on Kv1. 5 potassium channel on atrial fibrillation patients
下载PDF
导出
摘要 目的利用伊布利特特异性阻断超速延迟整流性钾通道(Kv1.5)后对缝隙连接蛋白(Cx)40表达的影响,探讨Kv1.5通道可能是心房肌缝隙连接蛋白下游信号传导通路之一,揭示心房颤动(AF)的可能发生机制。方法实验标本取自风湿性心脏病接受心脏瓣膜置换手术患者的右心耳组织,根据患者术前心律将标本分为2组:风湿性心脏病[窦性心律组(SR组)]和风湿性心脏病合并AF组(AF组)。采用酶解法分离风湿性心脏病接受手术患者心房肌细胞、培养心房肌细胞和运用Western blot技术检测两组心房肌细胞运用伊布利特特异性阻断Kv1.5通道前后Cx40的表达情况。结果利用伊布利特特异性阻断Kv1.5通道后,AF组患者心房心肌细胞Cx40的表达水平较阻断前明显增加(P<0.01);而在SR组中,阻断前后Cx40/GAPDH比值的变化不明显。结论 Kv1.5通道的开放状态可能会影响Cx40的表达,从而揭示AF的发生机制中电重构可能会引起结构重构。 Objective To evaluate the expression of atrial muscle gap junction Cx40 in rheumatic heart disease with chronic atrial fibrillation by using the new class Ⅲantiarrhythmie drug ibutilide specific block ultra-rapid delayed rectifier potassium channels( Kv1.5 ) , to discuss possibility of the Kv1.5 potassium channels to be one of downstream signal transduetion pathways of the atrial muscle gap junction protein,and to reveal the possible mechanism of atrial fibrillation (AF). Methods The experiment specimens were taken from right atrial appendage tissues of rheumatic heart disease patients who accepted the valve replacement surgeries, and these specimens were divided into 2 groups according to the heart rate before surgeries. The sinus rhythm group of rheumatic heart disease [ sinus rhythm (SR) group ], and the atrial fibrillation group of rheumatic heart disease heart disease ( AF group). Enzyme was used to dissociate atrial myocytes, atrial myocytes was cultured and Western blot was used to detect the protein expressions of Cx40 in two groups before and after they were selective acted on by the selective Kv1.5 potassium channel blocker-ibutilide. Results After using the Class Ⅲ antiarrhythmic agents to selective act on Kv1.5 potassium channel in rheumatic heart disease with chronic atrial fibrillation, the expression of Cx40 was significantly higher in AF group (P 〈 0.01 ). The protein expression of Kv1.5 was not significantly changed in SR group. Conclusion In the group of rheumatic heart disease with atrial fibrillation, the expression of Cx40 was significantly increased after using the specific inhibitor of Kv1.5 potassium channel blocker in AF group,proving that the open Kv1.5 potassium channels may affect the expression of connexin Cx40, which further reveals that electrical remodeling may lead to the diversification of structural remodeling in AF.
出处 《安徽医科大学学报》 CAS 北大核心 2013年第3期283-286,共4页 Acta Universitatis Medicinalis Anhui
基金 安徽高等学校省级自然科学研究重点项目(编号:KJ2011A175)
关键词 KV1 5钾通道阻滞剂 心房颤动 缝隙连接蛋白 ultra-rapid delayed rectifier potassium channels blocker atrial fibrillation connexin
  • 相关文献

参考文献15

  • 1Heeringa J,van der Kuip D A,Hofman A. Prevalence,incidence and lifetime risk of atrial fibrillation:the Rotterdam study[J].European Heart Journal,2006,(08):949-953.
  • 2郭志祥,葛圣林,周汝元,林敏,葛建军,高晴云,张士兵,张飞,李峰.慢性心房颤动患者右心耳CD11b、IL-6和TNF-α基因的表达[J].安徽医科大学学报,2007,42(1):30-33. 被引量:5
  • 3Bustamante J O,Watanabe T,McDonald T F. Nonspecific proteases:a new approach to the isolation of adult cardiocytes[J].Canadian Journal of Physiology and Pharmacology,1982,(07):997-1002.
  • 4黄从新,吴钢.心房颤动的药物治疗[J].中华心律失常学杂志,2008,12(3):175-178. 被引量:9
  • 5Brundel B J,Van Gelder I C,Henning R H. Alterations in potassium channel gene expression in atria of patients with persistent and paroxysmal atrial fibrillation:differential regulation of protein and mRNA levels for K+ channels[J].Journal of the American College of Cardiology,2001,(03):926-932.doi:10.1016/S0735-1097(00)01195-5.
  • 6邓玉莲,高峰,许春萱,张建成,陈林.心房颤动患者心房组织延迟整流钾通道基因表达的研究[J].中华心律失常学杂志,2005,9(6):445-448. 被引量:9
  • 7Petkova-Kirova P S,Gursoy E,Mehdi H. Electrical remodeling of cardiac myocytes from mice with heart failure due to the overexpression of tumor necrosis factor-alpha[J].American Journal of Physiology-Heart and Circulatory Physiology,2006,(05):H2098-H2107.
  • 8Knobloch K,Brendel J,Peukert S. Electrophysiological and antiarrhythmic effects of the novel I(Kur)channel blockers,S9947 and S20951,on left vs.right pig atrium in vivo in comparison with the I(Kr)blockers dofetilide,azimilide,d,l-sotalol and ibutilide[J].Naunyn-Schmiedeberg's Archives of Pharmacology,2002,(05):482-487.
  • 9Yang T,Snyders D,Roden D M. Drug block of I(kr):model systems and relevance to human arrhythmias[J].Journal of Cardiovascular Pharmacology and therapeutics,2001,(05):737-744.
  • 10Singh B N,Wadhani N. Antiarrhythmic and proarrhythmic properties of QT-prolonging antianginal drugs[J].Journal of Cardiovascular Pharmacology and therapeutics,2004,(Suppl 1):S85-S97.

二级参考文献41

  • 1宋兵,王邦宁,陈大年,骆志刚.房颤患者左房大小与血管性假血友病因子、D-二聚体及红细胞压积相关性[J].安徽医科大学学报,2005,40(1):84-85. 被引量:3
  • 2黄从新,马长生,杨延宗,黄德嘉,张澍,江洪,杨新春,吴书林,马坚,刘少稳,李莉,曹克将,王方正,陈新.心房颤动:目前的认识和治疗建议(二)[J].中华心律失常学杂志,2006,10(3):167-197. 被引量:269
  • 3黄从新,张澍,马长生,曹克将,杨延宗,刘旭,刘少稳,马坚,吴书林,江洪,黄德嘉,王方正,陈新.中国经导管消融治疗心房颤动注册研究[J].中华心律失常学杂志,2006,10(6):468-474. 被引量:29
  • 4Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation-Pharmacological Intervention in Atrial Fibrillation (PIAF) : a randomised trial. Lancet ,2000,356 : 1789-1794.
  • 5Van Gelder IC ,Hagens VE ,Bosker HA ,et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med ,2002,347 : 1834-1840.
  • 6Louis A, Cleland JG, Crabbe S, et al. Clinical Trials Update : CAP- RICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology,2001. Eur J Heart Fail,2001,3:381-387.
  • 7AFFIRM Investigators. Baseline characteristics of patients with atrial fibrillation: the AFFIRM Study. Am Heart J, 2002,143 : 991- 1001.
  • 8Opolski G, Torbicki A, Kosior DA, et al. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation : the results of the PoLish How to Treat Chronic Atrial Fibrillation ( HOT CAFE) Study. Chest,2004,126:476-486.
  • 9Epstein AE, Vidaillet H, Greene HL,et al. Frequency of symptomatic atrial fibrillation in patients enrolled in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. J Cardiovasc Electrophysiol,2002,13 : 667-671.
  • 10AFFIRM First Antiarrhythmic Drug Substudy Investigators. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the th.'st antiarrhythmic drug. J Am Coll Cardiol, 2003,42 : 20-29.

共引文献20

同被引文献96

  • 1童静,李鹏飞.Kv1.5钾离子通道阻滞剂的研究进展[J].中国药物化学杂志,2020,30(1):52-57. 被引量:4
  • 2田莉莉,黄从新,杨波.心房颤动患者Kv1.5 mRNA表达的研究[J].临床心血管病杂志,2004,20(6):343-344. 被引量:2
  • 3唐哨勇,王世敏,蒋学俊.电压依赖性Kv1.5通道的研究进展[J].国外医学(心血管疾病分册),2004,31(5):262-264. 被引量:6
  • 4邓玉莲,高峰,许春萱,张建成,陈林.心房颤动患者心房组织延迟整流钾通道基因表达的研究[J].中华心律失常学杂志,2005,9(6):445-448. 被引量:9
  • 5JONG Gwo-ping, CHANG Mu-hsin, CHANG Ting-chuan, CHOU Pesus, FU Chong-yau, TIEN Li-yun,CHEN Chung-yin and MA Tso-chiang,JONG Gwo-ping,CHANG Mu-hsin,CHANG Ting-chuan,CHOU Pesus,FU Chong-yau,TIEN Li-yun,CHEN Chung-yin,MA Tso-chiang.Long-term efficacy and safety of very-low-dose amiodarone treatment for the maintenance of sinus rhythm in patients with chronic atrial fibrillation after successful direct-current cardioversion[J].Chinese Medical Journal,2006(24):2030-2035. 被引量:6
  • 6Albrecht A, Kalil R A, Schuch L, et al. Randomized study of surgi-eal isolation of the pulmonary veins for correction of permanent at- rial fibrillation associated with mitral valve disease [ J ]. J Thorac Cardiovasc Surg,2009,138 ( 2 ) :454 - 9.
  • 7Kim J B, Ju M H, Yun S C,et al. Mitral valve replacement with or without a concomitant Maze procedure in patients with atrial fibril- lation[J]. Heart,2010,96(14) :1126 -31.
  • 8Fuster V, Ryden L E, Cannom D S, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text : a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Euro- pean Soeiety of Cardiology for Practice Guidelines ( Writing Com- mittee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the Europe- an Heart Rhythm Association and the Heart Rhythm Society [ J ]. Europace ,2006,9 ( 8 ) :651 - 745.
  • 9Baskin E P. Differential atrial versus ventricular activities of class III potassium channel blockers[ J]. J Pharmacol Exp Ther, 1998, 285(1) :135 -42.
  • 10Nair M, George L K, Koshy S K. Safety and efficacy of ibutilide in cardioversion of atrial flutter and fibrillation [ J ]. J Am Board Fam Med, 2011, 24(1) : 86 -92.

引证文献6

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部